<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753530</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00002461</org_study_id>
    <secondary_id>R01FD004809</secondary_id>
    <nct_id>NCT02753530</nct_id>
  </id_info>
  <brief_title>Study of Arimoclomol in Inclusion Body Myositis (IBM)</brief_title>
  <official_title>Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orphazyme</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Orphazyme</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source - FDA OOPD. The purpose of this study is to evaluate the safety and efficacy&#xD;
      of the study drug, Arimoclomol in IBM patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Actual">January 11, 2021</completion_date>
  <primary_completion_date type="Actual">January 11, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decline in Inclusion body myositis functional rating scale (IBMFRS)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
    <description>Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing (MMT)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum voluntary isometric contraction (MVICT) of quadriceps</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip and pinch test</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified timed up and go (mTUG)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk test with 2 minute distance captured</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire (HAQ-DI)</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
    <description>Measured using the Short form health survey with 36 items (SF-36).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Count of adverse events</measure>
    <time_frame>Change from Baseline to Month 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in Inclusion body myositis functional rating scale (IBMFRS)</measure>
    <time_frame>Change from Baseline to Month 12</time_frame>
    <description>Measured by rate of decline in the IBMFRS between experimental and placebo groups. The IBMFRS is a 10 item questionnaire. Scores for each item range from 0 to 4. There is a total maximum score of 40 and minimum score of 0. The higher the score the better functional status of the person.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">152</enrollment>
  <condition>Inclusion Body Myositis</condition>
  <arm_group>
    <arm_group_label>Arimoclomol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be asked to take 400mg arimoclomol three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be asked to take 400mg placebo three times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimoclomol</intervention_name>
    <description>2 200mg pills taken 3 times per day during breakfast, early afternoon and at bedtime</description>
    <arm_group_label>Arimoclomol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 matched placebo pills to be taken 3 times per day during breakfast, early afternoon and at bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet any of the European Neuromuscular Centre Inclusion Body Myositis research&#xD;
             diagnostic criteria 2011 categories for IBM&#xD;
&#xD;
          -  Demonstrate being able to arise from a chair without support from another person or&#xD;
             device&#xD;
&#xD;
          -  Able to ambulate at least 20 ft/6 meters with or without assistive device. Once arisen&#xD;
             from the chair, participant may use any walking device, i.e. walker/frame, can,&#xD;
             crutches, or braces. They cannot be supported by another person and cannot use&#xD;
             furniture or wall for support.&#xD;
&#xD;
          -  Body weight of &gt;= 40 kg&#xD;
&#xD;
          -  Pre-menopausal women must have a negative pregnancy tst prior to dosing iwht study&#xD;
             medication.&#xD;
&#xD;
          -  If a participant in the bimagrumab study, the participant must be off of the study&#xD;
             medication for at least 6 months.&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any of the following excludes subject participation in the study: chronic&#xD;
             infection particularly HIV or Hepatitis B or C; cancer other than basal cell cancer&#xD;
             less than five years prior; or other chronic serious medical illnesses.&#xD;
&#xD;
          -  Presence of any of the following on routine blood screening: WEB &lt;3000; platelets &lt;&#xD;
             100,000; hematocrit , 30%; BUN &gt; 30 mg%; creatinine &gt; 1.5 mg%; symptomatic liver&#xD;
             disease with serum albumin &lt; 3 g/dL.&#xD;
&#xD;
          -  History of most recent creatine kinase &gt;15x the upper limit of normal without any&#xD;
             other explanation besides IBM.&#xD;
&#xD;
          -  History of non-compliance with other therapies&#xD;
&#xD;
          -  Use of testosterone except for physiologic replacement doses in case of androgen&#xD;
             deficiency. Participants must have documented proof of the androgen deficiency.&#xD;
&#xD;
          -  Coexistence of other disease that would be likely to affect outcome measures.&#xD;
&#xD;
          -  Drug or alcohol abuse within past three months&#xD;
&#xD;
          -  Participation in a recent drug study in the last 30 days prior to the screening visit&#xD;
             or use of a biologic agent less than 6 months prior to the screening visit.&#xD;
&#xD;
          -  Women who are lactating or unwilling to use adequate method of birth control who are&#xD;
             not surgically sterile. Adequate birth control includes use of intrauterine device,&#xD;
             abstinence, or oral contraceptives or a double barrier method, e.g condom plas&#xD;
             diaphragm will be necessary for both male and female participants.&#xD;
&#xD;
          -  Participants taking &gt;7.5 mg prednisolone or equivalent or participants on IVIg or&#xD;
             other immunosuppressants within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazen Dimachkie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Hanna, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College, London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado School of Medicine</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nerve and Muscle Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College of London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myositis</mesh_term>
    <mesh_term>Myositis, Inclusion Body</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

